Shopping Cart 0
Cart Subtotal
AED 0

Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) and Selective Estrogen Receptor Modulators (SERMs)) for Male and Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 - 2021

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 15410

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 23117

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 30824
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

The report covers forecast and analysis for the osteoporosis drugs market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based revenue (USD Billion). The study includes drivers and restraints for the osteoporosis drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the osteoporosis drugs market on a global level. In order to give the users of this report a comprehensive view on the osteoporosis drugs market, we have to include competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug class segments and gender segments are benchmarked based on their market size, growth rate and general attractiveness. The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new drug class launch, agreements, partnerships, collaborations joint ventures, research development, drug class and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, drug class portfolio of various companies along with patent analysis (2011-2016) bifurcated into the patent trend, patent share by company and patent analysis according to the region. The study provides a decisive view on the osteoporosis drugs market by segmenting the market based on drug class, gender, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Based on drug class the market is segmented into bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs). Key gender market covered under this study includes male and female. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for osteoporosis drugs based on individual drug class and gender in all the regions and countries. The report also includes detailed profiles of end players such as Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd. This report segments the global osteoporosis drugs market as follows: Global Osteoporosis Drugs Market: Drug Class Segment Analysis Bisphosphonates Calcitonin Rank Ligand Inhibitors Parathyroid Hormone Therapy (PTH) Selective Estrogen Receptor Modulators (SERMs) Global Osteoporosis Drugs Market: Gender Segment Analysis Male Female Global Osteoporosis Drugs Market: Regional Segment Analysis North America U.S. Europe UK France Germany Asia Pacific China Japan India Latin America Brazil Middle East and Africa

READ MORE

Table Of Content

Scope

Chapter 1. Introduction 1.1. Report description and scope 1.2. Research scope 1.3. Research methodology 1.3.1. Market research process 1.3.2. Market research methodology Chapter 2. Executive Summary 2.1. Global osteoporosis drugs market, 2015 2021 (USD Billion) 2.2. Global osteoporosis drugs market : Snapshot Chapter 3. Osteoporosis drugs Market Dynamics 3.1. Introduction 3.2. Market drivers 3.2.1. Global osteoporosis drugs market drivers: Impact analysis 3.2.2. Increasing the prevalence of osteoporosis 3.3. Market restraints 3.3.1. Global osteoporosis drugs market restraints: Impact analysis 3.3.2. Side effects of osteoporosis drugs 3.4. Opportunities 3.4.1. Advancement in Research and development 3.5. Porters five forces analysis 3.5.1. Bargaining power of suppliers 3.5.2. Bargaining power of buyers 3.5.3. Threat from new entrants 3.5.4. Threat from new substitutes 3.5.5. Degree of competition 3.6. Market attractiveness analysis 3.6.1. Market attractiveness analysis, by drug class segment 3.6.2. Market attractiveness analysis, by gender segment 3.6.3. Market attractiveness analysis, by regional segment Chapter 4. Global Osteoporosis drugs Market Competitive Landscape 4.1. Company Market Share Analysis(Subject to data availability) 4.1.1. Global osteoporosis drugs market: company market share, 2015 4.2. Strategic Development 4.2.1. Acquisitions Mergers 4.2.2. New Drug class Launch 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures 4.2.4. Research and Development, Drug class and Regional Expansion 4.3. Product Portfolio 4.4. Patent Analysis (2011-2016) 4.4.1. Patent Trend 4.4.2. Patent Share by company 4.4.3. By Region Chapter 5. Global Osteoporosis Drugs Market Drug Class Segment Analysis 5.1. Global osteoporosis drugs market: Drug class overview 5.1.1. Global osteoporosis drugs market revenue share, by drug class, 2015 and 2021 5.2. Bisphosphonates 5.2.1. Global bisphosphonates market, 2015 2021(USD Billion) 5.3. Electromagnetic Blood Flowmeters 5.3.1. Global electromagnetic blood flowmeters market , 2015 2021(USD Billion) 5.4. Rank Ligand Inhibitors 5.4.1. Global rank ligand inhibitors market , 2015 2021(USD Billion) 5.5. Parathyroid Hormone Therapy (PTH) 5.5.1. Global parathyroid hormone therapy (PTH) market , 2015 2021(USD Billion) 5.6. Selective Estrogen Receptor Modulators (SERMs) 5.6.1. Global selective estrogen receptor modulators (SERMs) market , 2015 2021(USD Billion) Chapter 6. Global Osteoporosis Drugs Market Gender Segment Analysis 6.1. Global osteoporosis drugs market: Gender overview 6.1.1. Global osteoporosis drugs market revenue share, by gender, 2015 and 2020 6.2. Male 6.2.1. Global osteoporosis drugs market for male, 2015 2021 (USD Billion) 6.3. Female 6.3.1. Global osteoporosis drugs market for female, 2015 2021(USD Billion) Chapter 7. Global Osteoporosis Drugs Market Regional Segment Analysis 7.1. Global osteoporosis drugs market: Regional overview 7.1.1. Global osteoporosis drugs market revenue share, by region, 2015 and 2021 7.2. North America 7.2.1. North America osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.2.2. North America osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.2.3. U.S. 7.2.3.1. U.S. osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.2.3.2. U.S. osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.3. Europe 7.3.1. Europe osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.3.2. Europe osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.3.3. Germany 7.3.3.1. Germany osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.3.3.2. Germany osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.3.4. France 7.3.4.1. France osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.3.4.2. France osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.3.5. UK 7.3.5.1. UK osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.3.5.2. UK osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.4. Asia Pacific 7.4.1. Asia Pacific osteoporosis drugs market revenue, by drug class, 2015 2021, (USD Billion) 7.4.2. Asia Pacific osteoporosis drugs market revenue, by gender, 2015 2021, (USD Billion) 7.4.3. China 7.4.3.1. China osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.4.3.2. China osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.4.4. Japan 7.4.4.1. Japan osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.4.4.2. Japan osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.4.5. India 7.4.5.1. India osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.4.5.2. India osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.5. Latin America 7.5.1. Latin America osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.5.2. Latin America osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) 7.5.3. Brazil 7.5.3.1. Brazil osteoporosis drugs market revenue, by drug class, 2015 2021(USD Billion) 7.5.3.2. Brazil osteoporosis drugs market revenue, by gender, 2015 2021 (USD Billion) 7.6. Middle East and Africa 7.6.1. Middle East and Africa osteoporosis drugs market revenue, by drug class, 2015 2021 (USD Billion) 7.6.2. Middle East and Africa osteoporosis drugs market revenue, by gender, 2015 2021(USD Billion) Chapter 8. Company Profile 8.1. Novartis International AG 8.1.1. Overview 8.1.2. Financials 8.1.3. Product portfolio 8.1.4. Business strategy 8.1.5. Recent developments 8.2. Eli Lilly Amgen Inc 8.2.1. Overview 8.2.2. Financials 8.2.3. Product portfolio 8.2.4. Business strategy 8.2.5. Recent developments 8.3. Forteo 8.3.1. Overview 8.3.2. Financials 8.3.3. Product portfolio 8.3.4. Business strategy 8.3.5. Recent developments 8.4. Merck Co, Inc. 8.4.1. Overview 8.4.2. Financials 8.4.3. Product portfolio 8.4.4. Business strategy 8.4.5. Recent developments 8.5. Actavis plc 8.5.1. Overview 8.5.2. Financials 8.5.3. Product portfolio 8.5.4. Business strategy 8.5.5. Recent developments 8.6. Pfizer, Inc 8.6.1. Overview 8.6.2. Financials 8.6.3. Product portfolio 8.6.4. Business strategy 8.6.5. Recent developments 8.7. Teva Pharmaceutical Industries Ltd 8.7.1. Overview 8.7.2. Financials 8.7.3. Product portfolio 8.7.4. Business strategy 8.7.5. Recent developments 8.8. F. Hoffmann La Roche Ltd. 8.8.1. Overview 8.8.2. Financials 8.8.3. Product portfolio 8.8.4. Business strategy 8.8.5. Recent developments

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com